There was more than speculation earlier this year that the FDA asked Provectus to submit a BTD application. This "speculation" was confirmed in early June 2013.
You don't know that Greg. I stated that this would be a minmum of $2.50 by the end of the year. That's just over 6 months from now. Let's check then Greg.
Hi Greg. Hope all is well. You are so very wrong. We are all entitled to our opinions and perspectives. By then end of this year ETAK's SP will be at least $2.50. That's ~250% return from here. Let's check in again at teh end of the year. I have been loading up.
nowbehere - you may want to check the company's news today. Far more eloquent than I have been over the last two days. I do believe you will get a better sense now. Good luck to you.
Valuation too high or not merits a debate. You got the specific point that at today's value VRML is compelling. Hopefully my note was clear to others also
Correct. SGO does not endorse any product. They work hand in hand with ACOG for this area. The statement they made re OVA1 is effectively a precursor to guidelines from ACOG. Please DYOR if you do not understand the relationship between SGO and ACOG for this area.
GLTY and GLTA
The Society of Gynecologic Oncology (SGO) is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers. As a 501(c)(6) organization, the SGO contributes to the advancement of women’s cancer care by encouraging research, providing education, raising standards of practice, advocating for patients and members and collaborating with other domestic and international organizations.
google "sgo org ova1" from the link you will what was posted by this org last Friday (although the date saya May 2013) - they work hand in hand with ACOG
that SGO has "endorsed" OVA1 last Friday June 7. This is a precursor to ACOG providing guideliens as both work together in this area. Pressure abound to payers. So here's how I see valuation:
1 Total # of shares outstanding inc warrants 35MM
2 From Quest VRML currently receives $110 per test. Given the latest developments with Quest (company changing the dynamic as per their recent 8k) and with better payer coverage company will receive ~$220 per test
3 worldwide they will sell 500K tests per year
4 For company valuation it is appropriate to take top line revenue - i.e. $635 per test.
5 being conservative just taking $220 per test at 500k test per year equates to $110M annual revenue
6 $110M x 8 multiple = $880M (revenue will be recurring annually essentially)
7 $880M divided by 35MM shares equates to a SHARE PRICE OF $25.14 (twenty five dollars plus)
8 today's share price is $2.76
9 if we reduce multiple to conservative 5x value is $550m / 35MM shares which equates to a SP of $15.21 (fifteen dollars plus)
Whichever one chooses it is irrelevant. With SGO (and therefore ACOG round the corner and better payer coverage) a stock price of $2.76 is Christmas come early. GLTA
This is not guidelines, but as strong of a statement as you can get from sgo. THIS IS NOT OLD NEWS - came out late yesterday. This is a big deal. Of course shorts will say its not. Acog and sgo have worked together on this topic in the past, this sets the stage for acog changes, also makes it very difficult for payers not to cover the test.
The whole game is changing for vrml and we are in inning one.
Patent protects PVCT and ...
From a commercial perspective, the patent allowance also ensures that Provectus meets pharmaceutical manufacturing standards in important geographical regions worldwide including the United States, Australia, the EU, China, India and Japan.”
This is another significant positive development
absolute garbage. Artilium is doing ok and has recovered since the Robert Bonnier debacle. That said Artilium is a mere slither of what ETAK provides. ETAK will get to great places.